{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T22:43:28Z","timestamp":1784414608408,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ion Beam Applications, Louvain-la-Neuve, Belgium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [68Ga]Ga-DOTA-TATE. Al[18F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [68Ga]Ga-DOTA-TATE and Al[18F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [68Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[18F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adrenal glands (all p &lt; 0.001), pancreatic uncinated process, kidneys, and small intestine (all p &lt; 0.05). Nevertheless, despite the lower background uptake of Al[18F]F-NOTA-Octreotide, comparative analysis of tumour-to-liver (TLR) and tumour-to-spleen (TSR) showed no statistically significant difference for lesions in the liver, bone, lymph nodes, and other tissues. Only three discordant lesions in highly-metastases livers were detected by [68Ga]Ga-DOTA-TATE but not by Al[18F]F-NOTA-Octreotide and only one discordant lesion was detected by Al[18F]F-NOTA-Octreotide but not by [68Ga]Ga-DOTA-TATE. Non-inferiority analysis showed that Al[18F]F-NOTA-Octreotide is comparable to [68Ga]Ga-DOTA-TATE. Hence, our results demonstrate that Al[18F]F-NOTA-Octreotide provided excellent image quality, visualized NET lesions with high sensitivity and represents a highly promising, clinical alternative to [68Ga]Ga-DOTA-TATE.<\/jats:p>","DOI":"10.3390\/cancers15020439","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T02:27:12Z","timestamp":1673317632000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Al[18F]F-NOTA-Octreotide Is Comparable to [68Ga]Ga-DOTA-TATE for PET\/CT Imaging of Neuroendocrine Tumours in the Latin-American Population"],"prefix":"10.3390","volume":"15","author":[{"given":"Arlette","family":"Haeger","sequence":"first","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-4083","authenticated-orcid":false,"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"},{"name":"Positronpharma SA, Providencia, Santiago 7500921, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"},{"name":"Positronpharma SA, Providencia, Santiago 7500921, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Hurtado de Mendoza","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-2070","authenticated-orcid":false,"given":"Elisabeth","family":"Eppard","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"},{"name":"Department of Nuclear Medicine, University Hospital Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Ion Beam Applications, 1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Wettlin","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"},{"name":"Positronpharma SA, Providencia, Santiago 7500921, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-8536","authenticated-orcid":false,"given":"Ren\u00e9","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET\/CT Center PositronMed, Providencia, Santiago 7501068, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","article-title":"Neuroendocrine tumours","volume":"11","author":"Barakat","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminoncol.2018.07.001","article-title":"Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years","volume":"45","author":"Sackstein","year":"2018","journal-title":"Semin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_7","first-page":"336","article-title":"Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors","volume":"20","author":"Tomita","year":"2020","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_8","first-page":"1315","article-title":"Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs","volume":"44","author":"Hofland","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.apradiso.2013.01.039","article-title":"Clinical applications of Gallium-68","volume":"76","author":"Banerjee","year":"2013","journal-title":"Appl. Radiat. Isot."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_13","first-page":"5","article-title":"Chilean experience using \u201cTheranostics\u201d for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE","volume":"6","author":"Amaral","year":"2020","journal-title":"Arch. Clin. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13550-021-00797-4","article-title":"Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: Comparison with (68)Ga-DOTATATE PET\/CT","volume":"11","author":"Hou","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","article-title":"Clinical Application of 18F-AlF-NOTA-Octreotide PET\/CT in Combination With 18F-FDG PET\/CT for Imaging Neuroendocrine Neoplasms","volume":"44","author":"Long","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7150\/thno.31806","article-title":"The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development","volume":"9","author":"Waldmann","year":"2019","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2967\/jnumed.109.066902","article-title":"A novel facile method of labeling octreotide with (18)F-fluorine","volume":"51","author":"Laverman","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13277-011-0250-x","article-title":"Optimized labeling of NOTA-conjugated octreotide with F-18","volume":"33","author":"Laverman","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.111.088906","article-title":"Targeting somatostatin receptors: Preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET","volume":"52","author":"Leyton","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","article-title":"Al(18)F-NOTA-octreotide: First comparison with (68)Ga-DOTATATE in a neuroendocrine tumour patient","volume":"46","author":"Pauwels","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","article-title":"[(18)F]AlF-NOTA-octreotide PET imaging: Biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients","volume":"47","author":"Pauwels","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pauwels, E., Cleeren, F., Tshibangu, T., Koole, M., Serdons, K., Boeckxstaens, L., Dekervel, J., Vandamme, T., Lybaert, W., and Van den Broeck, B. (2022). (18)F-AlF-NOTA-octreotide outperforms (68)Ga-DOTA-TATE\/-NOC PET in neuroendocrine tumor patients: Results from a prospective, multicenter study. J. Nucl. Med., 64.","DOI":"10.2967\/jnumed.122.264563"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41181-019-0084-1","article-title":"Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide","volume":"5","author":"Tshibangu","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/ALN.0b013e3181ec6212","article-title":"Equivalence and noninferiority testing in anesthesiology research","volume":"113","author":"Mascha","year":"2010","journal-title":"Anesthesiology"},{"key":"ref_25","unstructured":"R Core Team (2013). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","article-title":"Physics of pure and non-pure positron emitters for PET: A review and a discussion","volume":"3","author":"Conti","year":"2016","journal-title":"EJNMMI Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(13)70048-2","article-title":"Planning cancer control in Latin America and the Caribbean","volume":"14","author":"Goss","year":"2013","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:17Z","timestamp":1760119517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020439"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020439","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}